v3.25.2
Reportable segment disclosure
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Reportable segment disclosure
Note 16: Reportable segment disclosure

Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Clinical studies16,258 13,056 23,060 21,229 
BLA & Regulatory2,298 1,610 3,683 3,090 
Medical Affairs & Other Medical2,009 1,626 3,967 4,290 
Research & Innovation342 575 1,086 765 
Manufacturing & Supply and Quality12,786 8,507 23,380 17,403 
Sales & Marketing419 986 681 1,744 
General & Administrative 8,463 8,643 14,089 16,447 
Total expenses42,575 35,003 69,946 64,968 
The Company operates and is managed as one operating segment driving expenses for the development of the Viaskin Peanut patch. The Company’s R&D organization is primarily responsible for the development and registration efforts of the Viaskin Peanut patch. The Company’s technical operations group is responsible for the development of manufacturing processes, supplying clinical drug product. The Company is also supported by corporate staff functions.
The Company’s Chief Executive Officer as the CODM manages and allocates resources to the operations of the total company by assessing the overall level of resources available and how to best allocate them to support the Company’s long-term company-wide strategic goals. In making this decision, the CODM uses consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods.
The CODM's analysis includes a comparison to budgeted results. Segment assets provided to the CODM are consistent with those reported on the Consolidated Statement of Financial Position with particular emphasis on the Company's available liquidity including cash, cash equivalents.